{
  "name": "21 CFR 314.50 Technical Component and eCTD Module Mapping Matrix",
  "description": "Comparative matrix mapping 21 CFR 314.50 regulatory sections to ICH electronic Common Technical Document (eCTD) modules, primary documentation mandates, and 21 CFR 314.101 filing risk factors.",
  "page": "https://casrai.org/guides/21-cfr-314-50",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-20T10:46:21Z",
  "temporalCoverage": "2026",
  "spatialCoverage": "United States",
  "columns": [
    {
      "name": "CFR Section",
      "unit": "",
      "description": "Specific regulatory paragraph under Title 21 CFR Section 314.50"
    },
    {
      "name": "Component Name",
      "unit": "",
      "description": "Official regulatory component name designated by FDA regulations"
    },
    {
      "name": "eCTD Module",
      "unit": "",
      "description": "Corresponding target location in the ICH electronic Common Technical Document structure"
    },
    {
      "name": "Statutory Focus",
      "unit": "",
      "description": "Core technical, scientific, or legal requirement established by the regulation"
    },
    {
      "name": "Filing Review Risk",
      "unit": "",
      "description": "Common omission or deficiency that triggers Refusal to File action under 21 CFR 314.101(d)(3)"
    }
  ],
  "rows": [
    {
      "CFR Section": "314.50(a)",
      "Component Name": "Application Form",
      "eCTD Module": "Module 1 (1.2)",
      "Statutory Focus": "Executed Form FDA 356h, establishment listings, and authorized US agent countersignature",
      "Filing Review Risk": "Missing signed Form FDA 356h or absent US agent authorization for foreign sponsors"
    },
    {
      "CFR Section": "314.50(c)",
      "Component Name": "Technical Summary",
      "eCTD Module": "Module 2 (2.2-2.7)",
      "Statutory Focus": "Comprehensive scientific synthesis of labeling, foreign marketing history, CMC, nonclinical, PK, and benefit-risk balance",
      "Filing Review Risk": "Inadequate synthesis of data or omission of foreign regulatory marketing history"
    },
    {
      "CFR Section": "314.50(d)(1)",
      "Component Name": "Chemistry, Manufacturing, and Controls",
      "eCTD Module": "Module 3 (3.2)",
      "Statutory Focus": "Drug substance and drug product specifications, synthesis, impurities, batch records, container closure, stability data",
      "Filing Review Risk": "Incomplete primary batch stability data or unvalidated analytical methodology"
    },
    {
      "CFR Section": "314.50(d)(2)",
      "Component Name": "Nonclinical Pharmacology and Toxicology",
      "eCTD Module": "Module 4 (4.2)",
      "Statutory Focus": "In vitro and in vivo animal pharmacology, safety pharmacology, pharmacokinetics, and pivotal GLP toxicology studies",
      "Filing Review Risk": "Omission of required GLP compliant systemic or reproductive toxicity study reports"
    },
    {
      "CFR Section": "314.50(d)(3)",
      "Component Name": "Human Pharmacokinetics and Bioavailability",
      "eCTD Module": "Module 5 (5.3.1-5.3.2)",
      "Statutory Focus": "In vivo bioavailability, bioequivalence, PK/PD relationships, metabolism, and dose-proportionality data",
      "Filing Review Risk": "Absence of required human bioavailability data without an approved regulatory waiver"
    },
    {
      "CFR Section": "314.50(d)(4)",
      "Component Name": "Microbiology Section",
      "eCTD Module": "Module 3 / Module 5",
      "Statutory Focus": "Antimicrobial spectrum, mechanisms of action, resistance profiles, and clinical microbiology correlations for anti-infectives",
      "Filing Review Risk": "Omission of antimicrobial susceptibility testing standards for anti-infective agents"
    },
    {
      "CFR Section": "314.50(d)(5)",
      "Component Name": "Clinical Data Section",
      "eCTD Module": "Module 5 (5.3.5)",
      "Statutory Focus": "Integrated Summary of Efficacy (ISE), Integrated Summary of Safety (ISS), and complete Phase 1-3 clinical trial reports",
      "Filing Review Risk": "Failure to provide pooled integrated safety datasets (ISS) or critical individual CRFs"
    },
    {
      "CFR Section": "314.50(d)(6)",
      "Component Name": "Statistical Section",
      "eCTD Module": "Module 5 (5.3.5)",
      "Statutory Focus": "Statistical analysis plans, multiplicity adjustments, handling of missing data, and electronic CDISC analysis datasets",
      "Filing Review Risk": "Missing CDISC SDTM or ADaM analysis datasets or unvalidated statistical analysis code"
    },
    {
      "CFR Section": "314.50(d)(7)",
      "Component Name": "Pediatric Use Section",
      "eCTD Module": "Module 1 (1.3.4)",
      "Statutory Focus": "Pediatric assessment under PREA, initial pediatric study plan (iPSP), or approved deferral or waiver documentation",
      "Filing Review Risk": "Omission of an agreed initial pediatric study plan (iPSP) or pediatric assessment documentation"
    },
    {
      "CFR Section": "314.50(h)",
      "Component Name": "Patent Information",
      "eCTD Module": "Module 1 (1.3.5.1)",
      "Statutory Focus": "Patent declarations submitted on Form FDA 3542a for Orange Book listing of drug substance, product, or use claims",
      "Filing Review Risk": "Missing Form FDA 3542a patent declarations or inaccurate patent claim listings"
    },
    {
      "CFR Section": "314.50(i)",
      "Component Name": "Patent Certification",
      "eCTD Module": "Module 1 (1.3.5.2)",
      "Statutory Focus": "Paragraph I, II, III, or IV patent certifications or Section viii statement for 505(b)(2) applications",
      "Filing Review Risk": "Defective Paragraph IV patent notice certification or invalid reference listed drug citation"
    },
    {
      "CFR Section": "314.50(j)",
      "Component Name": "Claimed Exclusivity",
      "eCTD Module": "Module 1 (1.3.5.3)",
      "Statutory Focus": "Factual justifications for 5-year NCE, 3-year clinical, orphan drug, or pediatric exclusivity protection",
      "Filing Review Risk": "Unsubstantiated exclusivity request or missing certification of active sponsor investigations"
    },
    {
      "CFR Section": "314.50(k)",
      "Component Name": "Financial Disclosure",
      "eCTD Module": "Module 1 (1.3.4)",
      "Statutory Focus": "Clinical investigator financial disclosures submitted on Form FDA 3454 or Form FDA 3455 under 21 CFR Part 54",
      "Filing Review Risk": "Incomplete investigator financial disclosures or missing declarations for covered studies"
    }
  ],
  "sources": [
    {
      "title": "Electronic Code of Federal Regulations: 21 CFR 314.50 - Content and format of an NDA",
      "url": "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.50",
      "accessed": "2026-11-20"
    },
    {
      "title": "Cornell Law School Legal Information Institute: 21 CFR 314.101 - Filing an NDA and receiving an ANDA",
      "url": "https://www.law.cornell.edu/cfr/text/21/314.101",
      "accessed": "2026-11-20"
    },
    {
      "title": "U.S. Food and Drug Administration: Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications",
      "accessed": "2026-11-20"
    }
  ]
}